	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR
Total Revenue	38.84	70.53	99.12	114.22	135.64	155.71	189.63
Cost of Operating Revenue	30.72	55.51	77.37	81.91	106.90	122.21	130.66
Gross Profit	8.12	15.02	21.75	32.31	28.74	33.50	58.98
Gross Margin	20.9	21.3	21.9	28.3	21.2	21.5	31.1
Total Operating Expenses	36.94	66.23	89.72	99.52	119.78	139.79	-
Operating Profit	1.90	4.30	9.40	14.71	15.86	15.92	-
Operating Margin	4.9	6.1	9.5	12.9	11.7	10.2	-
Financing Income/(Expense) - Net	-1.24	-1.16	-1.70	-3.10	-1.32	-2.61	0.12
Profit before Taxes	1.24	3.77	8.63	12.95	15.21	11.57	17.84
Income Taxes	0.37	1.04	1.95	3.14	3.71	3.73	3.64
Profit after Tax	0.93	2.72	6.11	9.49	11.30	8.15	-
PAT Margin	2.4	3.9	6.2	8.3	8.3	5.2	-
EPS - Basic - ex Extraordinary Items	0.67	1.96	4.39	9.33	8.12	5.60	7.80
EPS - Diluted - ex Extraordinary Items	0.67	1.96	4.39	9.33	8.12	5.60	7.80
EBIT	1.90	4.30	9.40	14.71	15.86	15.92	15.58
EBITDA	2.48	4.95	10.03	16.05	18.53	19.21	18.64
EBITDA Margin	6.4	7.0	10.1	14.0	13.7	12.3	9.8

Balance Sheet

Abridged

Understanding Balance Sheet

Infinium Pharmachem Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	PR	PR	PR	AR	AR	AR	AR
Total Current Assets	18.17	25.47	43.68	51.31	65.01	139.92	110.00
Long-Term Investments	-	-	-	-	-	29.02	29.02
Property Plant & Equipment - Net	4.16	8.58	12.68	18.81	19.65	21.61	28.23
Total Non-Current Assets	4.27	8.71	15.32	19.30	20.44	58.47	64.94
Total Assets	22.45	34.18	59.00	70.61	85.45	198.39	174.94
Total Current Liabilities	12.44	21.17	31.45	36.77	17.41	63.59	28.67
Long Term Debt	5.66	5.79	13.62	10.06	7.81	10.00	7.64
Total Non-Current Liabilities	5.66	5.79	13.62	10.06	7.81	10.00	7.81
Total Liabilities	18.11	26.97	45.08	46.83	25.22	73.59	36.48
Total Shareholders' Equity	4.25	7.02	13.10	22.56	58.78	109.46	121.05
Minority Interest	0.09	0.19	0.82	1.22	1.45	15.33	17.41
Total Equity	4.34	7.22	13.92	23.78	60.23	124.80	138.46
Total Liabilities & Equity	22.45	34.18	59.00	70.61	85.45	198.39	174.94

Cash Flow

Abridged

Understanding Cash Flow Statement

Infinium Pharmachem Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	2.59	3.86	8.48	11.13	14.61	11.48	17.23
Working Capital - Increase/(Decrease)	-0.83	2.26	1.58	-5.66	-30.03	-44.21	16.51
Net CF from Operating Activities	1.76	6.11	10.06	5.47	-15.42	-32.73	31.06
Capital Expenditures - Net	1.11	5.08	7.18	5.14	3.80	12.05	9.28
Net CF from Investing Activities	-1.02	-4.98	-6.60	-4.94	-3.61	-27.31	-7.36
Stock - Issuance/(Retirement) - Net	-	-	-	-	25.26	41.10	-
Debt - LT & ST - Issuance/(Retirement) - Total	-	-	-	-	-	-	0.07
Net Cash Flow from Financing Activities	-	-	-	-	24.96	82.96	-28.75
Free Cash Flow to Equity	0.65	1.03	2.88	0.32	-19.22	-44.78	21.84
Free Operating CF net dividend	0.65	1.03	2.88	-2.00	-19.22	-44.78	21.37
Free Operating CF	0.65	1.03	2.88	-2.00	-19.22	-44.78	21.37

Business Segment Analysis

FY End:

Mar 25

Infinium Pharmachem Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Manufacturing of lodine based pharmaceutical intermediates (100.0%)₹ 12.05 Cr

Revenue / Sales

Manufacturing of lodine based pharmaceutical intermediates (100.0%)₹ 155.71 Cr

Assets

Manufacturing of lodine based pharmaceutical intermediates (100.0%)₹ 198.39 Cr

Operating Income

Manufacturing of lodine based pharmaceutical intermediates (100.0%)₹ 15.92 Cr

Regional Segment Analysis

FY End:

Mar 25

Infinium Pharmachem Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Domestic sales (71.8%)₹ 98.29 CrExport sales (28.2%)₹ 38.62 Cr

Historical Segment Analysis

Track how Infinium Pharmachem Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2024 Mar 31	2025 Mar 31
	2024 Mar 31	2025 Mar 31
Manufacturing of lodine based pharmaceutical intermediates	4	12

Frequently Asked Questions

What is the revenue of Infinium Pharmachem Ltd.?

The latest trailing twelve month revenue of Infinium Pharmachem Ltd. is ₹ 189.63 Cr, reflecting a 1-year growth of 21.79% and a 3-year CAGR of 18.41%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Infinium Pharmachem Ltd.?

The latest trailing twelve month net profit (PAT) of Infinium Pharmachem Ltd. is ₹ 12.15 Cr, with a 3-year earnings CAGR of -5.81%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Infinium Pharmachem Ltd.?

The trailing twelve month EBITDA of Infinium Pharmachem Ltd. is approximately ₹ 18.50 Cr (based on an operating margin of 9.76%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Infinium Pharmachem Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Infinium Pharmachem Ltd. is 7.80. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Infinium Pharmachem Ltd.?

The debt-to-equity ratio of Infinium Pharmachem Ltd. stands at 0.19. The interest coverage ratio is 6.60x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Infinium Pharmachem Ltd.?

The estimated book value per share of Infinium Pharmachem Ltd. is 86.98 (derived from a P/B ratio of 2.55 and market price of ₹ 222.10), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Infinium Pharmachem Ltd.?

The trailing twelve month operating cash flow of Infinium Pharmachem Ltd. is ₹ 31.06 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Infinium Pharmachem Ltd. report consolidated or standalone financials?

Infinium Pharmachem Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.